Mirati Therapeutics Inc (NASDAQ: MRTX), a clinical-stage targeted oncology company, has named Jenny Gizzi as its new vice president, Human Resources, it was reported yesterday.
Gizzi will report directly to Charles M Baum, MD, PhD, president and chief executive officer. In her role, she will be responsible for all aspects of the company's human resources operations and strategy, including managing the planning, development, implementation and administration of Mirati's human resources programs. She will also be responsible for long range human resources planning to assist Mirati with continued growth.
Gizzi joins Mirati Therapeutics with more than 20 years of experience in human resources, most recently serving as the head of Strategy & Operations, Business Insights and Analytics at Bristol-Myers Squibb. Earlier in her career at Bristol-Myers Squibb, Gizzi served as head of Human Resources for the Bay Area and Cambridge, and head of Global Talent for European Markets, Australia and Canada where her responsibilities included heading global talent for eight markets and 13 countries and leading the international team specialising in creation of overall talent strategy. Prior to her time at Bristol-Myers Squibb, she was head of Global Talent Acquisition for Illumina Inc where she was ultimately responsible for their talent function globally.
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
InSysBio agrees new collaborative project with BeOne Medicines
Physiomics secures new modelling contract with Numab Therapeutics
Mabwell reports first patient dosed with 7MW4911 in US trial
Atossa Therapeutics' founder and CEO named one of The Top 50 Healthcare Technology CEOs of 2025
Avacta secures FDA clearance for second pre|CISION oncology programme
Guardant Health and Merck enter multi-year oncology diagnostics collaboration
Akeso secures NMPA review acceptance for gumokimab in ankylosing spondylitis